Company Description
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.
It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells.
In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia.
Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.
The company is based in New York, New York.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Sandesh Seth |
Contact Details
Address: 100 Park Avenue, 23rd Floor New York, New York 10017 United States | |
| Phone | 646 677 3870 |
| Website | actiniumpharma.com |
Stock Details
| Ticker Symbol | ATNM |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001388320 |
| CUSIP Number | 00507W107 |
| ISIN Number | US00507W2061 |
| Employer ID | 88-0378336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sandesh C. Seth M.B.A., M.S. | Chief Executive Officer, Principal Financial Officer and Chairman |
| Dr. Paul Diamond Esq., Ph.D. | Vice President of Patent and Legal Counsel |
| Lynn M. Bodarky M.B.A. | Chief Business Officer |
| Dr. Madhuri Vusirikala M.D. | Vice President of Clinical Development BMT and Cellular Therapy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2026 | 10-Q | Quarterly Report |
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 26, 2026 | 8-K/A | [Amend] Current report |
| Feb 13, 2026 | 8-K | Current Report |
| Nov 26, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 5, 2025 | ARS | Filing |
| Nov 5, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Jul 29, 2025 | SCHEDULE 13G/A | Filing |